A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy

This is a biomarker research study — it is not testing a new treatment, but rather looking at blood and tumor samples from patients who are already receiving a combination of immunotherapy drugs (PD1/PDL1 and CTLA4 inhibitors) plus anti-blood vessel therapy for certain cancers. The goal is to find biological markers that predict which patients will respond to this combination. **You may be eligible if...** - You have metastatic colorectal cancer that is MSS (microsatellite stable) and not responding to PD1/PDL1 immunotherapy alone, OR - You have a solid tumor with MSI (microsatellite instability) that is not responding to PD1/PDL1 antibody alone - You are currently receiving dual immunotherapy (PD1/PDL1 + CTLA4 blockade) combined with anti-angiogenic treatment (drugs targeting blood vessel growth) **You may NOT be eligible if...** - You have an active non-gastrointestinal cancer that has not been cured (Lynch syndrome is still eligible) Talk to your doctor to see if this trial is right for you.